Active-ingredient Dossier

Ivacaftor

Active-ingredient Dossier for Ivacaftor (cystic fibrosis modulator). Australian brands, products, PBS listings, PBAC outcomes — compiled by arcimedes.

Brand: KALYDECO
Brand: ORKAMBI
Brand: SYMDEKO
Brand: TRIKAFTA
Therapeutic area: Rare Disease

What is

Ivacaftor Ivacaftor is a cystic fibrosis modulator.

Australian brands containing

Ivacaftor — KALYDECO — ORKAMBI — SYMDEKO

Therapeutic areas

Ivacaftor is registered in respiratory (2 brands) and rare disease (1 brand) therapeutic areas.

Sponsor landscape

Vertex Pharmaceuticals markets ivacaftor in Australia.

PBS and regulatory activity

One brand containing ivacaftor has a PBS-listed item, with the latest PBS schedule date of 1 May 2026. In the 2021–22 fiscal year, government expenditure on ivacaftor products was $116,050,866.87 across 6,517 prescriptions. The latest PBAC outcome was recorded on 1 March 2025, and the latest AusPAR was published on 5 February 2016.